Argenx Se (ARGX) Net Income towards Common Stockholders Growth (1y) (2017 - 2026)
Argenx Se (ARGX) Net Income towards Common Stockholders Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 18.47% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 92.37% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.29 Bn | 34.28 Bn | 959.66 Mn | 1,228.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 92.37% |
| Mar 31, 2026 | 116.57% |
| Dec 31, 2025 | -31.16% |
| Sep 30, 2025 | 276.61% |
| Jun 30, 2025 | 744.14% |
| Mar 31, 2025 | 374.36% |
| Dec 31, 2024 | 880.62% |
| Sep 30, 2024 | 225.84% |
| Jun 30, 2024 | 130.80% |
| Mar 31, 2024 | -313.35% |
| Dec 31, 2023 | -156.84% |
| Sep 30, 2023 | -130.91% |
| Jun 30, 2023 | -114.23% |
| Mar 31, 2023 | 112.71% |
| Dec 31, 2022 | 83.76% |
| Sep 30, 2022 | 200.61% |
| Jun 30, 2022 | 2,816.87% |
| Mar 31, 2022 | -661.88% |
| Dec 31, 2021 | -22.17% |
| Sep 30, 2021 | -34.86% |